SUTRO BIOPHARMA, INC. Quarterly Debt-to-equity in % from Q2 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Sutro Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2019 to Q3 2024.
  • Sutro Biopharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 255 %, a 72.2% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 255 +107 +72.2% Sep 30, 2024
Q2 2024 250 +143 +134% Jun 30, 2024
Q1 2024 244 +160 +189% Mar 31, 2024
Q4 2023 187 +116 +163% Dec 31, 2023
Q3 2023 148 +91.2 +160% Sep 30, 2023
Q2 2023 107 +62 +137% Jun 30, 2023
Q1 2023 84.4 +55.1 +188% Mar 31, 2023
Q4 2022 70.8 +46.5 +191% Dec 31, 2022
Q3 2022 57 +36.4 +177% Sep 30, 2022
Q2 2022 45.2 +26 +136% Jun 30, 2022
Q1 2022 29.4 +6.68 +29.5% Mar 31, 2022
Q4 2021 24.4 -6.61 -21.4% Dec 31, 2021
Q3 2021 20.6 -21.3 -50.8% Sep 30, 2021
Q2 2021 19.2 -33.8 -63.7% Jun 30, 2021
Q1 2021 22.7 -41.2 -64.5% Mar 31, 2021
Q4 2020 31 -26.1 -45.8% Dec 31, 2020
Q3 2020 41.9 -18 -30% Sep 30, 2020
Q2 2020 53 -85.1 -61.6% Jun 30, 2020
Q1 2020 63.9 Mar 31, 2020
Q4 2019 57.1 Dec 31, 2019
Q3 2019 59.9 Sep 30, 2019
Q2 2019 138 Jun 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.